Breaking News Instant updates and real-time market news.

NVS

Novartis

$85.65

-0.2 (-0.23%)

, INCY

Incyte

$78.62

-0.1 (-0.13%)

05:42
06/03/19
06/03
05:42
06/03/19
05:42

Novartis to present new data, trial updates in NSCLC at ASCO

Novartis (NVS) announced new data and clinical trial updates in non-small cell lung cancer, or NSCLC, at the ASCO 2019 Annual Meeting. This includes primary efficacy results from the GEOMETRY mono-1 Phase II clinical trial demonstrating that investigational MET inhibitor capmatinib shows promise as a potential treatment option for patients with locally advanced or metastatic NSCLC that harbor MET exon-14 skipping mutation. There are currently no approved targeted therapies to treat this particularly aggressive form of NSCLC. Results of the Phase II study will be presented at an oral session at ASCO. Primary analysis of investigational capmatinib in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic NSCLC harboring MET exon-14 skipping mutation. Overall response rate among patients receiving capmatinib was 68% for treatment-naive and 41% for previously treated patients; median duration of response was also clinically meaningful irrespective of prior line of therapy. Capmatinib is an investigational, oral and selective MET inhibitor licensed to Novartis by Incyte (INCY) in 2009. Under the Agreement, Incyte granted Novartis worldwide exclusive development and commercialization rights to capmatinib and certain back-up compounds in all indications.

NVS

Novartis

$85.65

-0.2 (-0.23%)

INCY

Incyte

$78.62

-0.1 (-0.13%)

  • 05

    Jun

  • 05

    Jun

  • 10

    Jun

  • 11

    Jun

  • 13

    Jun

  • 17

    Jun

NVS Novartis
$85.65

-0.2 (-0.23%)

05/17/19
FBCO
05/17/19
NO CHANGE
Target $68
FBCO
Outperform
Alcon off to 'solid start' post-Novartis spin, says Credit Suisse
Credit Suisse analyst Matt Miksic reiterated an Outperform rating on Alcon (ALC) and raised his price target to $68 from $66 following the company's quarterly results, saying Alcon is off to a "solid start" following the spinoff from Novartis (NVS), and says he is incrementally more bullish on the company's revenue and growth drivers.
05/20/19
RBCM
05/20/19
NO CHANGE
RBCM
RBC says posting hints at Zolgensma label potentially positive for PTC, Biogen
RBC Capital analyst Brian Abrahams noted a new posting on ClinicalTrials.gov that he said "looks like" an expanded access program for Zolgensma that he believes could possibly offer some hints as to the potential label under discussion with the FDA. The most interesting parts are the inclusion criteria, which he thinks could "represent a middle ground" in terms of the breadth of label Novartis (NVS) could obtain for the drug. If the posting is predictive of Zolgensma's initial label, he said he would see it as an incremental positive for Biogen (BIIB), as it would potentially reduce the worst-case scenario of Zolgensma being approved with no age or weight restrictions. It would also be an incremental positive for PTC Therapeutics (PTCT), which Abrahams noted is looking to enter the space.
05/20/19
FBCO
05/20/19
INITIATION
Target $336
FBCO
Neutral
Regeneron initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.
05/24/19
FBCO
05/24/19
NO CHANGE
FBCO
Underperform
Zolgensma label breadth on higher end of expectations, says Credit Suisse
Credit Suisse analyst Evan Seigerman noted that the FDA announced approval for Novartis' (NVS) Zolgensma for the treatment of Spinal Muscular Atrophy, or SMA, in patients with bi-allelic mutations in the SMN1 gene under 2 years of age. The current wholesale acquisition cost for Biogen's (BIIB) Spinraza equates to a per-year treatment cost of $500,000 for the first year loading phase and $250,000-$375,000 per year for maintenance thereafter, which compares to a WAC of $2.125M for Zolgensma, which is administered just once, noted Seigerman. While investors generally expected Zolgensma would be approved, the breadth of the label was on the higher end of expectations, Seigerman tells investors. The pricing and label support his below consensus view of Spinraza, as he continues to expect that Zolgensma will become the preferred first option for infant-onset type 1 SMA, said the analyst, who reiterates his $198 price target and Underperform rating on Biogen shares.
INCY Incyte
$78.62

-0.1 (-0.13%)

05/03/19
LEHM
05/03/19
DOWNGRADE
Target $82
LEHM
Equal Weight
Incyte downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoffrey Meacham downgraded Incyte to Equal Weight from Overweight and lowered his price target for the shares to $82 from $90. With the stock up 27% year-to-date, the analyst does not see enough upside optionality from the company's graft-versus-host disease opportunity or its early-stage pipeline.
05/15/19
PIPR
05/15/19
NO CHANGE
Target $95
PIPR
Overweight
Incyte price target raised to $95 from $85 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren raised his price target for Incyte to $95 from $85 and reiterates an Overweight rating on the shares. The analyst models a U.S. atopic dermatitis and vitiligo launch in 2021 and 2023, respectively, with combined global sales surpassing $1B by the late 2020s. Incyte is "fully capable" of launching topical Jakafi in these indications with a specialty sales force of a couple hundred people, Van Buren tells investors in a research note. Further, the analyst notes that a key opinion leader Piper hosted was "very bullish" on topical Jakafi. The doctor believes that the efficacy of topical Jakafi exceeds that of the currently available non-steroidals, says Van Buren.
05/20/19
FBCO
05/20/19
INITIATION
Target $75
FBCO
Neutral
Incyte initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Incyte with a Neutral rating and $75 price target. The analyst wants to see more clinical evidence and trial execution in the company's its pipeline following last year's failure of epacadostat before coming more positive on the stock.
05/21/19
05/21/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Uber (UBER) initiated with an Equal Weight at Consumer Edge and a Neutral at Susquehanna. 2. Incyte (INCY) initiated with a Neutral at Credit Suisse. 3. Hillenbrand (HI) initiated with a Neutral at DA Davidson. 4. Target Hospitality (TH) initiated with a Buy at Deutsche Bank. 5. Jack in the Box (JACK) reinstated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

11:55
10/14/19
10/14
11:55
10/14/19
11:55
Conference/Events
JPMorgan telecom/networking equip analyst holds analyst/industry conference call »

Telecom & Networking…

VST

Vistra Energy

$27.00

-0.08 (-0.30%)

11:55
10/14/19
10/14
11:55
10/14/19
11:55
Options
Vistra Energy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDC

SmileDirectClub

$10.11

-0.99 (-8.92%)

11:50
10/14/19
10/14
11:50
10/14/19
11:50
On The Fly
SmileDirectClub drops after Dental Board of California sunset bill signed »

Shares of SmileDirectClub…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

RVNC

Revance

$13.01

0.84 (6.90%)

11:47
10/14/19
10/14
11:47
10/14/19
11:47
Recommendations
Revance analyst commentary  »

Stifel surprised by CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

HAL

Halliburton

$18.43

-0.515 (-2.72%)

11:45
10/14/19
10/14
11:45
10/14/19
11:45
Options
Halliburton call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 13

    Nov

NKE

Nike

$94.87

0.97 (1.03%)

, WDC

Western Digital

$59.11

0.75 (1.29%)

11:41
10/14/19
10/14
11:41
10/14/19
11:41
On The Fly
Nike, Western Digital upgrades among today's top analyst calls »

Check out today's top…

NKE

Nike

$94.87

0.97 (1.03%)

WDC

Western Digital

$59.11

0.75 (1.29%)

TPR

Tapestry

$24.94

-1.03 (-3.97%)

HPE

HP Enterprise

$14.77

0.42 (2.93%)

XLNX

Xilinx

$96.33

0.15 (0.16%)

DAL

Delta Air Lines

$52.71

-0.23 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 07

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

SDC

SmileDirectClub

$10.33

-0.77 (-6.94%)

11:32
10/14/19
10/14
11:32
10/14/19
11:32
Recommendations
SmileDirectClub analyst commentary  »

SmileDirectClub may have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

INTC

Intel

$51.65

-0.41 (-0.79%)

11:28
10/14/19
10/14
11:28
10/14/19
11:28
Periodicals
Intel may skip 10nm for desktop CPUs, Wccftech reports »

Intel is planning to skip…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 20

    Nov

BKNG

Booking Holdings

$1,985.99

11.08 (0.56%)

, FB

Facebook

$183.97

-0.23 (-0.12%)

11:25
10/14/19
10/14
11:25
10/14/19
11:25
Periodicals
Booking Holdings no longer supporting Facebook's Libra cryptocurrency, CNBC says »

CNBC Now tweeted…

BKNG

Booking Holdings

$1,985.99

11.08 (0.56%)

FB

Facebook

$183.97

-0.23 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

M

Macy's

$15.17

-0.56 (-3.56%)

11:25
10/14/19
10/14
11:25
10/14/19
11:25
Options
Macy's call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CARA

Cara Therapeutics

$19.13

0.29 (1.54%)

11:22
10/14/19
10/14
11:22
10/14/19
11:22
Recommendations
Cara Therapeutics analyst commentary  »

Stifel still optimistic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZUL

Azul

$37.10

0.25 (0.68%)

, UAL

United Airlines

$86.50

-0.68 (-0.78%)

11:20
10/14/19
10/14
11:20
10/14/19
11:20
Periodicals
Azul in talks to join United, Copa, Avianca partnership, Reuters reports »

Brazilian airline Azul…

AZUL

Azul

$37.10

0.25 (0.68%)

UAL

United Airlines

$86.50

-0.68 (-0.78%)

CPA

Copa Holdings

$98.68

-0.67 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 12

    Nov

  • 14

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
10/14/19
10/14
11:17
10/14/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
10/14/19
10/14
11:16
10/14/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

$20.96

0.305 (1.48%)

11:15
10/14/19
10/14
11:15
10/14/19
11:15
Options
Kemet put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

I

Intelsat

$24.59

0.26 (1.07%)

11:05
10/14/19
10/14
11:05
10/14/19
11:05
Options
Intelsat call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$169.81

-1.16 (-0.68%)

11:03
10/14/19
10/14
11:03
10/14/19
11:03
Hot Stocks
Deere to acquire Unimil, terms not disclosed »

Deere & Company has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SDC

SmileDirectClub

$10.48

-0.62 (-5.59%)

11:01
10/14/19
10/14
11:01
10/14/19
11:01
Hot Stocks
Breaking Hot Stocks news story on SmileDirectClub »

SmileDirectClub says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

SDC

SmileDirectClub

$10.44

-0.66 (-5.95%)

11:00
10/14/19
10/14
11:00
10/14/19
11:00
Hot Stocks
SmileDirectClub says CA assembly bill 1519 creates 'unnecessary hurdles' »

SmileDirectClub issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TPR

Tapestry

$24.69

-1.28 (-4.93%)

10:55
10/14/19
10/14
10:55
10/14/19
10:55
Options
Tapestry put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

10:55
10/14/19
10/14
10:55
10/14/19
10:55
Conference/Events
Evercore REITs analyst to hold a luncheon »

REITs Analyst Sakwa holds…

PUBGY

Publicis

$0.00

(0.00%)

, DIS

Disney

$129.71

-0.37 (-0.28%)

10:54
10/14/19
10/14
10:54
10/14/19
10:54
Periodicals
Disney splitting $3B media business with Publicis, Omnicom, Campaign reports »

Disney (DIS) is set to…

PUBGY

Publicis

$0.00

(0.00%)

DIS

Disney

$129.71

-0.37 (-0.28%)

OMC

Omnicom

$74.82

0.17 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 24

    Oct

  • 24

    Oct

  • 07

    Nov

ALXN

Alexion

$99.63

0.37 (0.37%)

10:45
10/14/19
10/14
10:45
10/14/19
10:45
Options
Alexion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

WDC

Western Digital

$59.26

0.9 (1.54%)

, AAPL

Apple

$237.68

1.47 (0.62%)

10:39
10/14/19
10/14
10:39
10/14/19
10:39
On The Fly
Western Digital rises as analyst says buy on rising flash prices »

Shares of Western Digital…

WDC

Western Digital

$59.26

0.9 (1.54%)

AAPL

Apple

$237.68

1.47 (0.62%)

STX

Seagate

$53.60

-0.2 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 01

    Nov

  • 04

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

HUM

Humana

$264.13

-2.2 (-0.83%)

10:34
10/14/19
10/14
10:34
10/14/19
10:34
Hot Stocks
Humana among five MA plans selected for Florida Medicare retirees »

Humana (HUM), which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.